Impact of disease-modifying therapies in adults with concomitant psoriatic and metabolic liver disease with integrated immunoprofiling

Effectiveness of biological disease-modifying antirheumatic drugs in progressive pulmonary fibrosis associated with rheumatoid arthritis.

OBJECTIVES To evaluate the effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA)-associated progressive pulmonary fibrosis (PPF). METHODS Real-world data were retrospectively collected in RA-associated PPF during the first year after bDMARD initiation. The...

Predictors of Treatment Response to Biological Medications in Patients with Rheumatoid Arthritis

Background: Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease characterized primarily by persistent synovitis, progressive joint destruction, functional impairment, and reduced quality of life. Biological disease-modifying antirheumatic drugs (bDMARDs) have substantially improved the manag...

Effect of JAK inhibitors on extraintestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease.

Clinical Impact of Fingolimod-Associated Lymphopenia in Multiple Sclerosis: A Real-World Cohort Study

Fingolimod-associated lymphopenia was common, with Grade 4 lymphopenia affecting approximately one-tenth of patients; however, the small number of Grade 4 cases, low event rate and wide confidence interval limited the statistical power to exclude clinically meaningful differences.

Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence

Background/Objectives: Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), show substantial variability in response to biologic therapies. Ustekinumab, which targets the IL-12/23 pathway, is an established treatment for moderate-to-severe IBD; however, a proportion of patients...

Predictors at diagnosis for initiation of biologic or targeted synthetic disease-modifying anti-rheumatic drugs in patients with spondyloarthritis and psoriatic arthritis

There is limited data on factors predicting the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs/tsDMARDs) in Spondyloarthritis (SpA) and Psoriatic arthritis (PsA). The relative importance of objective inflammation and other patient factors in this context is unclear. A retr...